Key Highlights
•
A new oral version of the chemotherapy drug paclitaxel, called DHP107, has been developed and tested against the traditional intravenous (IV) version for breast cancer. This is important because the oral pill could eliminate the need for long IV infusions and reduce common side effects like severe allergic reactions and nerve damage.
Source →
•
A study found that a specific dose of the COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) is safe and effective for patients with severe kidney disease, including those on dialysis. This is crucial because this high-risk group was previously excluded from using this life-saving drug due to concerns about it building up to toxic levels in their bodies.
Source →
•
Researchers have mapped out how stomach cancers that are initially treatable with HER2-targeted drugs become resistant to therapy. They identified several escape routes the cancer uses, including changing its cell type and activating other survival pathways. This knowledge is key to designing new drug combinations that can outsmart the cancer and make treatments last longer.
Source →
•
For lung cancer patients who also have a pre-existing lung scarring disease (interstitial lung disease), immunotherapy drugs (ICIs) significantly extend life compared to standard chemotherapy. This finding is vital for clinical practice because it shows that the survival benefit of these powerful drugs outweighs their known increased risk of causing further lung inflammation in this vulnerable group.
Source →
•
A systematic review found no increased risk of brain swelling or bleeding (ARIA) in Alzheimer’s patients taking both new anti-amyloid antibody drugs and blood thinners (anticoagulants). This challenges current safety warnings and could allow more patients with common heart conditions like atrial fibrillation to access these promising new Alzheimer’s treatments.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
